Serious adverse events occurred in a global clinical trial and if India is also a part of global trial then, the SAEs should be submitted to DCGI.
An excerpt from ICH-E2A guideline: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (Section III A, B, C)
All adverse drug reactions (ADRs) that are both serious and unexpected are subject to expedited reporting. This applies to reports from spontaneous sources and from any type of clinical or epidemiological investigation, independent of design or purpose. It also applies to cases not reported directly to a sponsor or manufacturer (fro example, those found in regulatory authority-generated ADR registries or in publications). The source of a report (investigation, spontaneous, other) should always be specified.
Expedited reporting of recations which are serious but expected will ordinarily be inappropriate. Expedited reporting is also inappropriate for serious events from clinical investigations that are considered not related to study product, whether the event is expected or not. Similarly, non-serious adverse reactions whether expected or not, will ordinarilty not be subject to expedited reporting.
Information obtained by a sponsor or manufacturer on serious, unexpected reports from any source should be submitted on an expedited basis to appropriate regulatory authorities if the minimum criteria for expedited reporting can be met.
The CIOMS-I from has been a widely accepted standard for expedited adverse event reporting. All reports must be sent to those regulators or other official parties requiring them 9as appropriate for the local situation) in countries where the drug is under development.